CytoSorbents Corporation (CTSO)

[andy55q]

A retrospective analysis of efficacy of hemoadsorption (CytoSorb®) in refractory septic shock patients as an adjuvant
Surendra M, Cherukuri B, Kumar S, Harithra N, Kantham L, Silpa CN, Bhavya, Srikanth, Jyothi Y. International Journal of Scientific Research 2019; 8(19): 1 – 3
10/2019
This retrospective study included eight patients with refractory septic shock (defined as unresponsive to inotropic and vasopressor support – dopamine ³15mcg/kg/min, noradrenaline³0.25 mcg/kg/min) treated with CytoSorb. Patients were relatively young (age range 19 – 39 yrs) with a variety of causes for their sepsis. Six out of the 8 patients could be stabilized after 24hrs of CytoSorb treatment, completely recovered und survived. CytoSorb treatment appeared to be well tolerated in this patient population. Total leucocyte count, mean arterial blood pressure, lactate and vasopressor requirements all improved after 24 hours of CytoSorb therapy. This study reports that the use of CytoSorb as an adjunctive therapy along with standard therapy in a high risk group of septic shock patients with organ damage appears to improve their outcome.
less
Download document